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Background: The E3 ligase FANCL monoubiquitinates FANCD2 in a critical step in the repair of DNA interstrand
crosslinks.
Results: FANCL binds ubiquitin non-covalently via its N-terminal E2-like fold.
Conclusion:Monoubiquitination of FANCD2 is regulated via a non-covalent interaction between FANCL and ubiquitin.
Significance: This interaction represents an additional layer of regulation of the Fanconi Anemia pathway, and a targetable
interface.
TheFanconiAnemia (FA)DNArepair pathway is essential for
the recognition and repair of DNA interstrand crosslinks (ICL).
Inefficient repair of these ICL can lead to leukemia and bone
marrow failure. A critical step in the pathway is the monoubiq-
uitination of FANCD2 by the RING E3 ligase FANCL. FANCL
comprises 3 domains, a RING domain that interacts with E2
conjugating enzymes, a central domain required for substrate
interaction, and an N-terminal E2-like fold (ELF) domain. The
ELF domain is found in all FANCLhomologues, yet the function
of the domain remains unknown. We report here that the ELF
domain of FANCL is required to mediate a non-covalent inter-
action between FANCL and ubiquitin. The interaction involves
the canonical Ile44 patch on ubiquitin, and a functionally con-
served patch on FANCL. We show that the interaction is not
necessary for the recognition of the core complex, it does not
enhance the interaction between FANCL and Ube2T, and is
not required for FANCD2 monoubiquitination in vitro. How-
ever, we demonstrate that the ELF domain is required to pro-
mote efficient DNA damage-induced FANCD2 monoubiquiti-
nation in vertebrate cells, suggesting an important function of
ubiquitin binding by FANCL in vivo.
Fanconi Anemia (FA)3 is an autosomal recessive or X-linked
inherited childhood disorder, characterized by bone marrow
failure and a high incidence of cancer (1, 2). Biallelic mutations
in any of 16 currently identified FA genes results in failure to
repair DNA interstrand crosslinks (ICL), which can occur dur-
ing replicative stress and upon encountering endogenous geno-
toxins (3–9).
A key step in DNA ICL repair is the site-specific monoubiq-
uitination of FANCD2 at Lys561 (10), which leads to the
recruitment of downstream repair factors. This monoubiquiti-
nation event is carried out by FANCL, the RING E3 ligase sub-
unit of the FA core complex (11, 12). In vertebrates, the FA core
complex comprises 9 proteins: FANCA, FANCB, FANCC,
FANCE, FANCF, FANCG, FAAP100, FAAP20, and FANCL,
reviewed in Ref. 13. Recent studies have shown that the core
complex members FANCB, and FAAP100 are required for full
ubiquitin ligase activity in cells (14, 15). Previous work has also
suggested that FANCL is required for core complex assembly
(16). Intriguingly, while FANCL as the functional ligase subunit
is conserved in invertebrates, there are no identifiable homo-
logs of FANCB or FAAP100 in lower eukaryotes. Indeed the
only additional core complex component found in an inverte-
brate is FANCE in Dictyostelium (17, 18).
The crystal structure of full-length FANCL revealed 3
domains (19), an N-terminal E2-like fold (ELF) domain, a cen-
tral double RWD (DRWD) domain, and a C-terminal RING
domain. The RING domain serves as an E2-conjugating
enzyme recruitment module, being necessary and sufficient for
the interactionwithUbe2T, the E2 for the FApathway (20–22).
The DRWD domain harbors the substrate binding site (19, 20,
23). However, the ELF domain has no known function and
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makes no contacts with the other domains of FANCL (19). The
ELF domain is found in all FANCL homologues, and is con-
served across species. Therefore, we sought to establish the
function of the ELF domain.We report here a previously unde-
tected non-covalent interaction between the ELF domain of
FANCL and ubiquitin. We use detailed biochemical and struc-
tural studies to characterize the interaction, and find that it is
mediated via a functionally conserved patch on ELF and the
hydrophobic patch of ubiquitin. Furthermore we show that the
interaction is neither catalytic, nor required for complex forma-
tion, but is required for efficient FANCD2monoubiquitination
in cells.
Experimental Procedures
Protein Expression and Purification—All mutants were gen-
erated with the QuikChange site-directed mutagenesis kit
(Stratagene). Drosophila melanogaster FANCL constructs and
DRWD-RING (105–431) were expressed and purified as
described previously (19).
The ELF domain (1–105) was cloned into the pET SUMO
vector. Luria Broth (LB) growth medium cultures were grown
at 37 °C until A600 0.6–0.8. After reducing the temperature to
16 °C, cells were grown toA600 0.8 before inducing with 250M
isopropyl -D-1-thiogalactopyranoside (IPTG). Cells were har-
vested in 500 mM NaCl, 100 mM Tris, pH 8.0, 250 M Tris(2-
carboxyethyl)phosphine (TCEP), sonicated and clarified before
affinity purification using Ni-NTA resin (Qiagen) and over-
night cleavage with the SUMO protease, Ulp1, in 50 mM NaCl,
100 mM Tris, pH 8.0, 250 M TCEP. The flow through was
loaded onto aQ SepharoseHP in 50mMNaCl, 100mMTris, pH
8.0, 250 MTCEP and eluted with a gradient including 500mM
NaCl. The purified ELF domain was flash frozen and stored in
50 mM Tris, pH 8.0, 200 mM NaCl, 250 M TCEP, and 5% (v/v)
glycerol at80 °C.
Human ubiquitin was cloned into pRSF Duet-1 vector with
no purification tag. Luria Broth (LB) growth medium cultures
were grown at 37 °C until A600 0.5, at which point expression
was induced with 500 M IPTG for 4 h. Cells were harvested
and resuspended in PBS buffer before repelleting and flash
freezing in liquid nitrogen. The pellets were resuspended in 1
mM EDTA, 25 mM Tris, pH 8.0 before sonication and clarifica-
tion. The clarified lysate was filtered and loaded ontoQSephar-
ose HP (GE Healthcare) anion exchange column equilibrated
25 mM Tris, pH 8.0, 1 mM EDTA. The ubiquitin came off in the
unbound fraction, before further purification with size exclu-
sion chromatography 250 mM NaCl, 100 mM Tris, pH 8.0 and
subsequent storage at80 °C.
For His-ubiquitin, human ubiquitin was cloned into the
pRSF Duet-1 vector with a N-terminal Hexa-His tag. Expres-
sion was induced with 0.5 mM IPTG at A600 0.5 followed by
batch affinity purification on Ni-NTA (Qiagen) as above. His-
ubiquitin was eluted with 300 mM imidazole and further puri-
fied by size exclusion chromatography. All interaction experi-
ments are done using monoubiquitin.
Xenopus laevis STREP-FANCD2 cDNA was a kind gift from
P. Knipscheer and J. Walter. We expressed and purified the
protein as previously described (24). Briefly, Hi5 cells were
infected with baculovirus, and the protein was purified on
FLAG resin before elution with 3 FLAG peptide and stored
with 5% glycerol at80 °C.
Xenopus tropicalis—FANCL was expressed and purified as
previously described (21).
Pull-down Assays—In a total reaction volume of 1 ml con-
taining assay buffer, 500mMNaCl, 100mMTris, pH 8.0, 250M
TCEP and 10 M ZnCl2, Drosophila FANCL, FANCL L81R,
ELF, DRWD-RING,Xenopus FANCL, or FANCLN72R (all 250
nM) was added with an excess of His-ubiquitin (1 M), His-
Ube2T (500 nM) or His-Ube2T-Ub (500 nM). Reactions were
left to bind for 1 h on ice. 100 l of Ni-NTA-agarose (Qiagen)
was equilibrated in assay buffer and added to the 1 ml reaction
and left on a roller at 4 °C for 1 h. Samples were washed with 10
ml of assay buffer and the agarose resuspended in 100 l of
assay buffer. 50 l of 2 SDS buffer was added before the sam-
ples were boiled. 10l of the samples was loaded onto SDS page
gel and subjected to Western blotting and probed with appro-
priate antibodies. Anti-ubiquitin antibody was purchased from
DAKO. Anti-Drosophila FANCL and anti-humanDRWDanti-
bodies were raised from recombinant proteins by Pettingill
Technology Ltd. The anti-His antibodywas purchased fromGE
Healthcare.
NMR Spectroscopy and ELF Assignment—The Drosophila
ELF domain and ubiquitin were isotopically labeled by overex-
pression in minimal medium enriched with [15N]ammonium
sulfate and [13C]glucose. For NMR samples the ELF domain
and ubiquitin were buffer exchanged into 50 mM NaCl, 20 mM
sodium phosphate, pH 6.5. Susceptibility matched NMR tubes
(Shigemi, US) were used at all stages. Sample volumes of 330l
were placed in Shigemi BMS-005V tubes and included 10%
D2O v/v. Themajority of NMR experiments were carried out at
600 MHz using a VarianUnity INOVA equipped with a 5 mm
HCN z-pulse field gradient probe. Chemical shift referencing
was based on the position of the water resonance with the exact
value being related to the known relationship of the H2O reso-
nance with temperature. Unless otherwise stated, all NMR
experimentswere solvent suppressed to reduce thewater signal
usingWATERGATE that was typically obtained using gradient
field strengths of 40–50 G cm1. All NMR datasets were
acquired at 25 °C.
All NMR data processing utilized NMRPipe (25) and ana-
lyzed using the CCPN analysis package (26). Most resonances
were successfully assigned manually without ambiguity. Back-
bone chemical shift assignments were achieved for the ELF
domain using 1H-15N HSQC, CBCA(CO)NH, CBCANH, 15N-
NOESY-HSQC, and 15N-TOCSY-HSQC experiments. Previ-
ous amide chemical shift assignments for human ubiquitin
were obtained from the VLI Research, Inc. Web site and were
used to assign resonances in the ubiquitin 1H-15N HSQC.
NMR Titrations—All titration experiments were recorded in
50 mM NaCl, 20 mM sodium phosphate, pH 6.5. The 15N-la-
beled domain (wild type ELF or ubiquitin) was at 0.6 mM in the
sample, while the binding partner was titrated in at different
molar ratios (10:1, 7:5:1, 5:1, 2.5:1, 1:1). All 15N-1H HSQCwere
recorded for 30 min.
Isothermal Titration Calorimetry (ITC)—Kinetic informa-
tion of the Drosophila ELF domain binding interactions with
ubiquitin was established using the ITC200 microcalorimeter
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(MicroCal, Northampton, MA). Sample buffers were 50 mM
Tris, pH 8.0, 100 mM NaCl. Experiments were carried out at
30 °C. The syringe contained 40l of 2.5mMubiquitin, with 2.5
l injections every 200 s. The cell contained 205 l of 230 M
ELF domain. Cell concentrations were adjusted to a 1:1 stoi-
chiometric interaction and Microcal Origin software version
7.0 was used to determine the dissociation constants (Kd). All
measurements were repeated at least twice.
DT40 Cell Studies—FANCL-deficient DT40 cells (fancl/)
and fancl/ complemented with TAP-tagged wild-type
FANCL (TAP-FANCL) were described recently (27). Point
mutations L7A, D78A, D78R, L79A, and V80A were generated
by site-directed muagenesis (QuickChange II XL site-directed
mutagenesis kit; Stratagene). DT40 cell transfections, DT40
subfractionation, Superpose 6 gel size chromatography, and
FANCD2 immunoblot analyses were described previously (27).
To assess TAP-FANCL interaction with ubiquitin, fancl/
cells expressing either TAP-FANCL or TAP-FANCL (L7A,
D78R, L79A)were lysed inTAP-buffer (50mMTris, pH 8.0, 200
mM NaCl, 0.5 mM EDTA, 0.1% Nonidet P-40, and protease
inhibitor mixture (Roche Molecular Biochemicals)). TAP-
tagged FANCL variants were immunoprecipitated from 2 mg
lysates with 50 l of IgG-coupled Sepharose (GE Healthcare)
and washed extensively with Ub-binding buffer (UbBB) (50mM
Tris, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40, 2 mg/ml BAS).
TAP-FANCLSepharose beadswere homogenized inUbBB and
incubated with 10 mg/ml HA-tagged wild type or I44A-mu-
tated ubiquitin for 2 h at 4 °C. Beads were washed with wash
buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 0.2% Nonidet
P-40). Bound ubiquitin was analyzed by immunoblotting with
anti-HA (Bethyl Laboratories).
Ube2T Autoubiquitination Assay—100 l reactions were
setup containing 3MHis-Ube2T, 227 nM E1, 28MHis-ubiq-
uitin with either 9 M of E3 (WT Drosophila FANCL, L81R
Drosophila FANCL, orDrosophilaDRWD-RING) or water in a
buffer containing 5 mM ATP, 50 mM Tris, pH 7.5, 100 mM KCl,
0.5 mM DTT, and 2 mM MgCl2. Subsequently, 10 l samples
were removed from each assay at 0, 15, 20, and 30 min, and
arrested with 10 l LDS buffer (Invitrogen) containing 400 mM
-mercaptoethanol (-ME). Half of each sample was subjected
to Western blot analysis using an anti-His antibody (GE
Healthcare).
Charging Ube2T—ChargedUbe2Twas prepared by adapting
the method described in Ref. 28. Human His-Ube2T C24S and
FIGURE 1. FANCL binds ubiquitin via the N-terminal E2-like fold. A, pull-down of FANCL species by ubiquitin shows that ubiquitin binding is mediated by
the ELF domain. Each experiment is probedwith anti-His-ubiquitin and anti-FANCL antibodies, with the input, bait, andbeads controls indicated. B, isothermal
titration calorimetry curve showing binding of the ELF domain to ubiquitin. Dissociation constant and stoichiometry of the interaction are indicated.
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tag-free ubiquitin G76C were purified to homogeneity as
before, albeit retaining the His-tag on Ube2T. These were then
dialyzed against 50 mM sodium borate, pH 8.0, 1 mM TCEP
overnight. The proteins were mixed for 15 min on ice with
His-Ube2T at 330Mand ubiquitin at 1mM.A stock solution of
1,3 dichloroacetone (Sigma) was prepared in dimethylforma-
mide at 20mM. This was added to themixed proteins at 0.8 mM
and the samples were left rolling at 4 °C for 1 h. The reaction
was quenched with 10 mM -ME for 1 h. The sample was then
loaded onto an SD75 16/60 column (GE Healthcare) and puri-
fied, and the protein stored at80 °C with 10% glycerol.
Monoubiquitination of Xenopus FANCD2—Ubiquitination
reactions were performed at 30 °C in a 50 mM Tris, pH 7.5, 100
mMKCl, 2mMMgCl2, 5% (v/v) glycerol, and 0.5mM dithiothre-
itol (DTT) buffer system. Reactions contained 25 nM of recom-
binant human E1, 0.5 M of Ube2T, 1 M of indicates E3 spe-
cies, 0.5 M of Xenopus FANCD2, and 2 mM ATP in 20 l of
final reaction volume.
Complete ubiquitination profile was analyzed using fluores-
cently labeled ubiquitin (Ub800). Ubiquitin (residues 2–76) was
expressed and purified bearing a GPLCGS overhang at the N
terminus. The cysteine residue in the overhangwas targeted for
site-specific incorporation of a DyLight™ 800 Maleimide (Life
Technologies) dye following the manufacturer’s protocol.
Labeled species was further subject to cation exchange chro-
matography and stored at 20 °C as single-use aliquots. All
ubiquitination reactions contained 2M of Ub800 and were ter-
minated by boiling with LDS loading buffer. The samples were
resolved by SDS-PAGE and analyzed by direct fluorescence
monitoring using Li-COR Odyssey Infrared Imaging System.
Integrated intensitiesofFANCD2ubiquitination fromfive inde-
pendent experiments were obtained using Image Studio™
(Odyssey) imaging software and plotted using GraphPad
Prism.
Results
FANCL Binds Ubiquitin Non-covalently—The ELF domain
of FANCL shares significant structural homology with E2-con-
jugating enzymes (19). E2s form a catalytic intermediate with
ubiquitin via a thioester between the catalytic cysteine and the
C terminus of ubiquitin (29). The ELF domain does not possess
a catalytic cysteine.However, an additional feature of E2s is that
they can also interact non-covalently with ubiquitin (30, 31).
Therefore we hypothesized that the ELF domain of FANCL
might interact with ubiquitin in a similar manner. To test this
hypothesis, we performed a pull-down binding assay using 6
His-tagged ubiquitin as bait (Fig. 1A). His-ubiquitin pulls down
both full-length Drosophila FANCL and the isolated ELF
domain. In contrast, FANCL lacking the ELF domain (ELF)
is not pulled down. To further characterize the interaction
between the ELF domain and ubiquitin, wemeasured the affin-
ity of binding using isothermal titration calorimetry (ITC), and
determined a dissociation constant of 42 12.0 M (Fig. 1B).
A Surface-exposed Patch on the ELF Domain Interacts with a
Hydrophobic Patch on Ubiquitin—We next wanted to under-
stand the molecular determinants of the interaction between
FANCL and ubiquitin. E2s bind ubiquitin non-covalently via a
backside interaction that involves residues from the loop con-
necting strands 2 and 3 (30) (Fig. 2A). The dissociation con-
stant between ubiquitin and the ELF domain suggests that crys-
tallization of the complex would prove challenging. Indeed,
despite extensive efforts, we were unable to obtain high-resolu-
FIGURE 2. Structural assignment of theDrosophila ELF domain. A, superposition of the ELF domain fromDrosophila FANCL in blue (PDB 3K1L) (19) with the
E2Ube2L3 in yellow (PDB1FBV) (48). E2protein-protein interaction surfaces indicated, as is thepositionof the catalytic cysteineofUbe2L3.B, assignment of the
Drosophila ELF domain 1H-15N HSQC. The cross-peaks in the 1H-15N HSQC were assigned to residues in the primary sequence of the Drosophila ELF domain.
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tion diffracting crystals. Therefore, to understand the mode of
ubiquitin binding by the ELF domain and whether it is similar
to that seen in E2s, we set out to map the interacting surfaces
using Nuclear Magnetic Resonance (NMR) spectroscopy. For
both structural studies and ITC, milligram quantities of high-
quality protein are required. The mammalian and vertebrate
homologues of FANCL are not amenable to large scale soluble
expression (20, 23); therefore, we used the more soluble inver-
tebrate ELF domain from Drosophila, which shares 65%
sequence similarity (19% identity) with the human ELF domain
(19). First, we determined the solution structure of the ELF
domain. Two-dimensional 15N-1H HSQC NMR of the 15N-la-
beled ELF domain yielded clear and resolved spectra, with
excellent chemical shift dispersion, characteristic of a folded
globular domain. We unambiguously assigned 76 out of 104
ELF residues using triple-resonance backbone datasets (Fig.
2B). Once we had determined the positions of each residue of
the ELF domain in the spectra, we then titrated in increasing
amounts of ubiquitin and recorded changes in the two-dimen-
sional 15N-1H HSQC. Upon addition of ubiquitin, resonances
were broadened to the extent that they were no longer visible,
indicating a specific but transient interaction between the pro-
teins (Fig. 3A). We then performed the reciprocal experiments
by titrating increasing wild type ELF domain into 15N-labeled
ubiquitin, and identified the binding site on ubiquitin (Fig. 3B).
The interaction surface on the ELF domain involves a surface
comprising residues Leu-53, His-54, Leu-74, Leu-76, and
Leu-81 (Fig. 4,A and B). The interaction surface on ubiquitin is
FIGURE 3. Reciprocal titrations of FANCL ELF domain and ubiquitin indicate interaction between both proteins. A, 15N-1H HSQC of the 15N labeled ELF
domain during titration of wild type ubiquitin. Wild type ELF domain spectra are denoted in black, with 5:1 ELF to ubiquitin in blue and 1:1 in red. The box is a
zoom of a portion of the spectra. B, 15N-1H HSQC of 15N-labeled ubiquitin during titration of wild-type ELF. Wild type ubiquitin spectra are in black, with 5:1
ubiquitin to ELF in blue and 1:1 in red. The box is a zoom of a portion of the spectra.
FANCL-Ubiquitin Interaction Regulates the FA Pathway
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the Leu8-Ile44-Val70 central hydrophobic patch commonly
recognized by ubiquitin-binding proteins (Fig. 4, A and B) (32).
These results reveal a novel interaction surface on the ELF
domain. This surface is not a relic of the E2-like fold, as it does
not coincide with the predicted surface upon overlaying the
structures (Figs. 2A and 4, C andD). To assess the requirement
FIGURE 4.A solvent-exposed patch on the ELF domain interacts with the hydrophobic Ile44 patch of ubiquitin. A, graphical representation of the shifts
in cross-peaks in the spectra of the ELF domain upon titration of unlabeled ubiquitin. B, graphical representation of the shifts in cross-peaks in the spectra of
ubiquitin upon titration of unlabeled ELF domain. The y axis represents the percentage decrease in cross-peak height for each residue between the wild-type
1H-15NHSQCand the 1H-15NHSQC recordedwith5:1 15N-labeledprotein.C, ribbondiagramof theDrosophilaELFdomain (inpurple) andubiquitin (inblue)with
residues involved in binding highlighted in red. D, surface representations of the Drosophila ELF domain (in purple) and ubiquitin (in blue) with residues
involved in binding shown in red.
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FIGURE 5.Mutation of the ELF domain abolishes binding. A, ITC curves showing lack of interaction between ubiquitin and L81R ELF domain. B, ITC curves
showing lack of interaction between the ELF domain and I44A ubiquitin. C, 1H-15NHSQC spectra of wild-type DmELF domain (blue) overlaidwith 1H-15NHSQC
spectra of DmELF-L81R (red). The overlay shows the structure, fold, and stability of both proteins are comparable. The inset shows a Coomassie-stained gel of
the proteins used in these experiments.
FANCL-Ubiquitin Interaction Regulates the FA Pathway
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for residues in the interaction surfaces, we sought to validate
our structural insights. We mutated residues involved in the
binding, and assayed the resulting proteins for interaction using
ITC. The ELF domain point mutant L81R completely abolishes
binding (Fig. 5A), as does the ubiquitin mutant I44A (Fig. 5B).
To test whether the leucine to arginine mutation on the
exposed solvent-accessible surface of the ELF domain disrupts
the folding of the domain, we performed two-dimensional
15N-1H HSQC NMR of the 15N-labeled L81R-ELF domain.
These experiments yielded clear and resolved spectra, with
excellent chemical shift dispersion, characteristic of a folded
globular domain, with small changes compared with the wild-
type spectra, consistent with a well-folded, stable, mutant pro-
tein (Fig. 5C).
Ub Binding Is a Conserved Function of Vertebrate and Inver-
tebrate ELF Domain—The residues in the ELF domain that are
important for ubiquitin binding are not well conserved (Fig.
6A). However, ubiquitin-interacting proteins and motifs such
as CUE domains, UBAs, UIMs, andMIUs often share very little
sequence homology yet retain functional homology (33). We
therefore wanted to determine whether the function of ubiqui-
tin binding is conserved in vertebrate FANCL homologs. We
and others had difficulties to make wild type full-length human
FANCL, therefore we turned to the Xenopus system. Indeed.
Xenopus tropicalis FANCL recapitulates ubiquitin binding (Fig.
6B). Mutation of Asn-72, corresponding to Leu-81 in the Dro-
sophila protein, results in almost a complete loss of interaction
with ubiquitin, indicating that the same region in FANCL is
required for interaction with ubiquitin (Fig. 6B), and that the
interaction is conserved between species.
FANCL-Ubiquitin Binding Does Not Enhance the Interaction
with Charged Ube2T or Aid Ube2T Discharge—Several E2-
RINGE3 ligase interactions are enhanced by the presence of the
ubiquitin thioester bound on the E2 (34, 35). Therefore another
explanation is that FANCL interactionwith ubiquitin enhances
the recognition of ubiquitin-charged Ube2T (Ube2TUb).
To test this hypothesis, we generated a stable Ube2TUb ester
and assayed FANCL binding via pull-down. We observed no
difference in the levels of FANCL binding in a comparison
between ubiquitin-charged Ube2T and uncharged Ube2T (Fig.
7A). Furthermore, there was no difference in Ube2TUb bind-
ing when the ubiquitin binding surface of ELF was mutated.
These data suggest that ubiquitin binding does not enhance
FANCL’s interaction with E2.
Although ubiquitin binding does not enhance interaction
with Ube2TUb, it may be required for efficient discharge of
the ubiquitin thioester. Since Ube2T auto-monoubiquitinates
(22), and FANCL has been shown to stimulate this (22), we
performed a thioester discharge assay to test whether the ELF-
Ubiquitin interaction is important for this. We incubated full-
lengthDrosophila FANCL, FANCL L81R, orELFwith human
Ube2T, and monitored levels of Ube2T autoubiquitination.
Indeed, addition of FANCL, FANCL L81R, or ELF-deleted
FANCL (ELF), stimulated discharge of ubiquitin to the same
extent (Fig. 7B). This suggests that the ELF domain is neither
enhancing discharge nor monoubiquitination and is thus not
catalytic.
Ubiquitin Binding Is Not Required for Efficient FANCD2
Ubiquitination in Vitro—We next asked whether FANCL’s
non-covalent interaction with ubiquitin is important for
FANCD2 monoubiquitination in vitro. Wild type FANCL sup-
ports FANCD2 monoubiquitination in vitro (Fig. 7C). Muta-
tion of the ubiquitin-binding patch in has no effect on the levels
of FANCD2 monoubiquitination, further suggesting that the
ubiquitin-binding by the ELF domain is not catalytic.
UbiquitinBinding by FANCL Is Required for EfficientMonou-
biquitination of FANCD2 inVertebrate Cells—Finally, we asked
whether ubiquitin binding by FANCL has any relevance to
FANCD2 monoubiquitination in cells. To test this hypothesis
we expressed ELF domain-mutated versions of TAP-tagged
FANCL in FANCL-deficient avianDT40 cells (fancl/). These
FANCL variants carry combinatorial point mutations of con-
served amino acids, L7A, D78A, D78R, L79A, V80A, that
assemble the ubiquitin binding surface determined from Dro-
sophila FANCL (Fig. 6A). Wild-type TAP-tagged FANCL
expression promotes efficient FANCD2 monoubiquitination
FIGURE 6. Ubiquitin binding is conserved in vertebrates. A, structure-based alignment of the ELF domain from various species of FANCL: Drosophila
melanogaster (Dm), human (Hs), mouse (Mm), chicken (Gg), Xenopus tropicalis (Xt), and Danio rerio (Dr). Conserved residues are shaded red, conservative
substitutions in orange, semi-conservative substitutions in yellow. Residues involved in ubiquitin-binding are boxed, and the Leu-81/Asn-72 residue is marked
with an asterisk. Structural elements are included above the sequence. B, pull-down of Xenopus Tropicalis FANCL by ubiquitin shows that ubiquitin binding is
conserved. Each experiment is probed with anti-His-ubiquitin and anti-FANCL antibodies, with the input, bait and beads controls indicated.
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both in high salt nuclear extracts (NEX) and soluble chromatin
extracts (CHEX) (Fig. 8). In contrast, TAP-FANCL (L7A,
L79A), TAP-FANCL (L7A, D78A, L79A, V80A), and TAP-
FANCL (L7A, D78R, L79A) are defective in mitomycin C
(MMC)-induced monoubiquitination of FANCD2 (Fig. 8, A
and B). In addition we compared time-dependent FANCD2
monoubiquitination following MMC treatment of wild-type
TAP-FANCL with ELF domain mutants FANCD2 monoubiq-
uitination followingMMC treatment of wild type TAP-FANCL
with ELFubiquitin bindingmutantsTAP-FANCL (L7A, L79A),
TAP-FANCL (L7A, D78A, L79A, V80A), and TAP-FANCL
(L7A,D78R, L79A) (Fig. 8,C andD). TAP-FANCL (L7A,D78A,
L79A, V80A), TAP-FANCL (L7A, D78R, L79A), and to a lesser
extent TAP-FANCL (L7A, L79A), showed a significant delay in
and overall reduction of FANCD2 monoubiquitination. More-
over, we observed a similar reduction ofMMC-induced FANCI
monoubiquitination (Fig. 8E).
FANCL was originally predicted to adopt a WD40-propeller
fold in place of the ELF-DRWD domains (12). In a previous
study based on this prediction, mutation of the predicted
WD40 repeats, including a large part of the ELF domain, was
found to disrupt assembly of the FA core complex (16). Since
the core complex is required for efficient FANCL-catalyzed
FANCD2 monoubiquitination in cells, we next assessed
whether the defective FANCI/FANCD2monoubiquitination in
TAP-FANCL (L7A, D78R, L79A) expressing cells was due to
FIGURE 7.Ubiquitin binding is not required for E2 recognition. A, pull-down analysis of the interaction betweenwild type and L81RDrosophila FANCL and
human Ube2T or Ube2T-Ub. Both FANCL species bound Ube2T and Ube2T-Ub to the same extent. B, Western blot analysis of Ube2T autoubiquitination in the
absence and presence of Drosophila FANCL WT, L81R, and ELF species. All variations of E3 were able to successfully stimulate discharge of ubiquitin from
Ube2Tonto itself.C, in-gel fluorescence analysis of in vitro FANCD2monoubiquitination (left). Ubiquitin is fluorescently labeled,withnoATPandnoE3 controls,
showing the modification of FANCD2. The right panel shown 5 independent replicates, with a Coomassie-stained loading control, and quantification of the
level of FANCD2 ubiquitination (bottom).
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FIGURE 8. Ubiquitin binding by FANCL is required for efficient FANCD2/FANCI monoubiquitination in vertebrate cells. A, FANCL-deficient DT40 cells
(fancl/) were complementedwith TAP-taggedwild-type FANCL (TAP-FANCL) and FANCLwithmutated ELF ubiquitin-binding sites (TAP-FANCL(L7A, L79A),
TAP-FANCL(L7A, D78A, L79A, V80A), TAP-FANCL(L7A, D78R, L79A)). Cells were either 150 nM MMC-treated () or mock treated (), and lysates were subfrac-
tionated intohigh salt nuclear extract (NEX) and soluble chromatin extract (CHEX). Equal total protein amount of extractswere separatedonSDS-PAGEgels and
analyzed by immunoblotting using anti-FANCD2 and anti-TAP antibodies. Mutations in the ELF ubiquitin-binding site perturbed MMC-induced FANCD2
monoubiquitination. D2-Ub, monoubiquitinated FANCD2; D2, unmodified FANCD2. B, quantitation of the various ratios of monoubiquitinated FANCD2 and
unmodified FANCD2 shown in A using ImageJ analysis software. Standard error of the mean is given from three independent experiments. C, cell lines
described in A were exposed to 150 ng/ml MMC, whole cell extract prepared after indicated times and subjected to FANCD2 immunoblot analysis. D,
quantitation of the various ratios of monoubiquitinated FANCD2 and unmodified FANCD2 shown in C using ImageJ analysis software. D, indicated cell lines
were treatedwith 600 nMMMC () ormock treated (), fractionated as described inA, and analyzedby immunoplotting using anti-FANCI and anti-TAP. FANCI
monoubiquitination was significantly reduced in ELF-mutated cells. I-Ub, monoubiquitinated FANCI; I, unmodified FANCI. F, TAP-tagged wild-type FANCL
(TAP-FANCL) andELF-mutated FANCL (TAP-FANCL [L7A,D78R, L79A])were affinity-purified fromcorrespondingDT40 cellswith IgG-Sepharose, and incubated
with either wild type HA-ubiquitin (WT) or I44Amutated HA-ubiquitin (I44A). Co-precipitation of the ubiquitin formswere analyzed by immunoplotting using
anti-HA. Mutating the ELF domain or the ubiquitin I44 hydrophobic patch disrupted the TAP-FANCL ubiquitin interaction.G, TAP-FANCL and TAP-FANCL (L7A
D78R L79A) high salt nuclear extracts were fractionated by Superose 6 size exclusion chromatography, and fractions were analyzed by immunoplotted using
anti-TAP. Elution profiles of a 1–1.5 MDa complex were comparable between wild type FANCL and the ELF domain mutated FANCL.
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disrupted ELF ubiquitin-binding rather than a destabilization
of the FAcore complex.We first testedTAP-FANCLubiquitin-
binding employing a cell free system. Affinity purified TAP-
FANCL interactedwithwild type ubiquitin, thatwas dependent
on the ubiquitin Ile-44 patch. Mutated TAP-FANCL (L7A,
D78R, L79A) however showed a significantly reduced ubiquitin
binding, confirming that amino acids Leu-7, Asp-78, and
Leu-79 encompass the ubiquitin interaction surface on chicken
FANCL (Fig. 8F).
Next we assayed the formation of the FA core complexes in
DT40 FANCL/ cells expressing TAP-tagged FANCL or
TAP-tagged ELF patch mutant TAP-FANCL (L7A, D78R,
L79A).We observed no difference in the pattern of highmolec-
ular weight complex formation (Fig. 7A), indicating that ubiq-
uitin binding is not required for the stable incorporation of
FANCL into the core complex. Notably, TAP-FANCL (L7A,
D78R, L79A) accumulates on damaged chromatin as efficient
as wild type TAP-FANCL, further supporting our data that
TAP-FANCL complex formation and integrity is independent
of ELF ubiquitin binding (Fig. 8G). Taken together, these data
suggest that in vertebrate cells, FANCI/FANCD2 monoubiq-
uitination is dependent on the FANCL interaction with ubiqui-
tin, mediated by the ELF domain.
Discussion
This study describes a hitherto unknownnon-covalent inter-
action between FANCL and ubiquitin, with an affinity com-
monly observed in ubiquitin-protein interactions (36), that is
required for efficient FANCD2monoubiquitination. The inter-
action between the ELF domain of FANCL and ubiquitin is
distinct from the surfaces in E2 proteins commonly used for
non-covalent ubiquitin binding. This suggests that rather than
being a relic of the E2 fold, ubiquitin binding is a function spe-
cific to FANCL. We define a function for the ELF domain,
which is conserved among FANCL species (19), although dis-
pensable in vitro for both substrate binding and catalysis of
FANCD2 monoubiquitination (19–21). Our finding that the
ubiquitin-binding patch of the ELF domain is required for effi-
cient FANCD2 monoubiquitination in cells suggest that ELF
domainmutations would be harmful. However, there are as yet
no FA patients identified with mutations in this domain.
Intriguingly, a recent study aimed at identifying breast cancer
susceptibility genes reports a significant occurrence of a splice
isoform of FANCL in a cohort of non-BRCA breast cancer
patients (37). The isoform results in removal of residues 72–91
of the ELF domain, which encompasses the ubiquitin-interact-
ing surface (Figs. 4C and 6A).
Our findings suggest that FANCLmay be binding an uniden-
tified ubiquitinated protein as a requisite step in themonoubiq-
uitination of FANCD2. We propose that a potential candidate
is the clamp loader, PCNA. ICL repair is a complex and multi-
step process, that also requires components of the translesion
synthesis (TLS) pathway (9, 38, 39). In common with the FA
pathway, the TLS pathway is also regulated by a site-specific
monoubiquitination event. PCNA is modified at Lys164 by the
ring E3 ligase, Rad18 (40–42). FANCL and Rad18 are epistatic
for ICL sensitivity and repair (43), and co-depletion of
FANCD2 and Rad18 does not increase cellular sensitivity to
cisplatin, suggesting the proteins function in the same pathway
(44). Rad18 does not monoubiquitinate FANCD2 (45). How-
ever, the E3 ligase activity of Rad18 is required for efficient
loading of FANCD2 onto chromatin (44). In addition to the
requirement for Rad18 activity, PCNAandFANCD2 interact in
cells (46). FANCL and PCNA are also reported to interact in
cells, via the central (DRWD) domain of FANCL (47). Although
the monoubiquitination of PCNA appears to be critical for
monoubiquitination of FANCD2, themolecular andmechanis-
tic details of this interplay are poorly understood. We propose
that the ELF domain of FANCL interacts with monoubiquiti-
nated PCNA, and thatmay act as a trigger for FANCD2monou-
biquitination, as observed by Geng et al. (47). Potentially,
monoubiquitinated PCNA reinforces the interaction between
FANCD2 and FANCI. Alternatively, given that monoubiquiti-
nation of PCNA is required for accumulation of FANCA on
chromatin (45), monoubiquitinated PCNA could aid in recruit-
ment of the core complex to sites of DNA damage and/or acti-
vation of FANCL. In summary, our data provide insights into
the regulation of the FA pathway, and provides the molecular
details of a required interaction, potentially representing a
druggable interface in the FA pathway.
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